/NWPHF

NWPHF Stock - Newron Pharmaceuticals S.p.A.

Q: What is the analyst price target for NWPHF?

Analyst price target information is not currently available for NWPHF.

Q: What is NWPHF's market cap?

Market capitalization information is not currently available for NWPHF.

Healthcare|Biotechnology|OTC

$12.00+5.26%

+$0.60 (+5.26%) • May 15

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $13.20

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NWPHF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.68

52W High$12.00

52W Low$5.22

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$51.39M	$9.06M	$6.09M	$5.76M	$5.26M
Gross Profit	$51.39M	$9.06M	$6.09M	$5.76M	$4.96M
Gross Margin	100.0%	100.0%	100.0%	100.0%	94.4%
Operating Income	$26.17M	$-11,629,000	$-13,302,000	$-12,357,000	$-18,066,000
Net Income	$15.84M	$-16,224,000	$-17,493,000	$-14,901,000	$-20,998,000
Net Margin	30.8%	-179.1%	-287.1%	-258.6%	-399.4%
EPS	$0.85	$-0.91	$-0.98	$-0.84	$-1.18

Company Overview

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Visit Website

Earnings History & Surprises

NWPHF

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$N/A

EPS Surprise History

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	Apr 17, 2024	—	—	—	—
Q1 2024	Mar 19, 2024	—	—	—	—

Frequently Asked Questions about NWPHF

What is NWPHF's current stock price?

Newron Pharmaceuticals S.p.A. (NWPHF) is currently trading at $12.00 per share. The stock has moved +5.26% today.

What is the analyst price target for NWPHF?

No analyst price targets are currently available for this stock.

What sector is Newron Pharmaceuticals S.p.A. in?

Newron Pharmaceuticals S.p.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is NWPHF's market cap?

Newron Pharmaceuticals S.p.A. has a market capitalization of $0.24 billion, making it a small-cap company.

Does NWPHF pay dividends?

No, Newron Pharmaceuticals S.p.A. does not currently pay a dividend to shareholders.